John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO Plenary Series 2022 – Abstract 360490: First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.
Brief Synopsis:
In adult individuals with KRAS p.G12C mutant advanced solid tumors, assess the safety and tolerability of AMG 510.
Advertisement
In adult participants with KRAS p.G12C mutant advanced solid tumors, calculate the maximum tolerated dosage (MTD) and/or a recommended phase 2 dose (RP2D).